HRP20050774A2 - Imidazol-4-yl-ethylnyl-pyridine derivatives - Google Patents

Imidazol-4-yl-ethylnyl-pyridine derivatives

Info

Publication number
HRP20050774A2
HRP20050774A2 HR20050774A HRP20050774A HRP20050774A2 HR P20050774 A2 HRP20050774 A2 HR P20050774A2 HR 20050774 A HR20050774 A HR 20050774A HR P20050774 A HRP20050774 A HR P20050774A HR P20050774 A2 HRP20050774 A2 HR P20050774A2
Authority
HR
Croatia
Prior art keywords
imidazol
pyridine
ylethynyl
disease
alkyl
Prior art date
Application number
HR20050774A
Other languages
English (en)
Croatian (hr)
Inventor
Buettelmann Bernd
Maria Ceccarelli Simona
Jaeschke Georg
Kolczewski Sabine
Hugh Phillip Porter Richard
Vieira Eric
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20050774A2 publication Critical patent/HRP20050774A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20050774A 2003-03-10 2005-09-05 Imidazol-4-yl-ethylnyl-pyridine derivatives HRP20050774A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004952 2003-03-10
PCT/EP2004/002276 WO2004080998A1 (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives

Publications (1)

Publication Number Publication Date
HRP20050774A2 true HRP20050774A2 (en) 2006-09-30

Family

ID=32981724

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050774A HRP20050774A2 (en) 2003-03-10 2005-09-05 Imidazol-4-yl-ethylnyl-pyridine derivatives

Country Status (31)

Country Link
US (1) US7153874B2 (xx)
EP (1) EP1606277B8 (xx)
JP (1) JP4404896B2 (xx)
KR (1) KR100742019B1 (xx)
CN (1) CN100358889C (xx)
AR (1) AR043501A1 (xx)
AT (1) ATE395345T1 (xx)
AU (1) AU2004220382B2 (xx)
BR (1) BRPI0408093A (xx)
CA (1) CA2516682C (xx)
CL (1) CL2004000449A1 (xx)
CO (1) CO5601027A2 (xx)
DE (1) DE602004013746D1 (xx)
DK (1) DK1606277T3 (xx)
ES (1) ES2305739T3 (xx)
HK (1) HK1089443A1 (xx)
HR (1) HRP20050774A2 (xx)
IL (1) IL170129A (xx)
MX (1) MXPA05009524A (xx)
MY (1) MY135491A (xx)
NO (1) NO20054136L (xx)
NZ (1) NZ541643A (xx)
PA (1) PA8597301A1 (xx)
PE (1) PE20041061A1 (xx)
PL (1) PL1606277T3 (xx)
PT (1) PT1606277E (xx)
RU (1) RU2342383C2 (xx)
SI (1) SI1606277T1 (xx)
TW (1) TWI292318B (xx)
WO (1) WO2004080998A1 (xx)
ZA (1) ZA200506834B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7452909B2 (en) * 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
PL1756086T3 (pl) * 2004-06-01 2008-11-28 Hoffmann La Roche Pirydyn-4-ylo-etynylo-imidazole i pirazole jako antagoniści receptora mGlu5
BRPI0511678A (pt) 2004-06-01 2008-01-08 Hoffmann La Roche piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MY148217A (en) 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8957213B2 (en) 2011-04-26 2015-02-17 Hoffman-La Roche Inc. Ethynyl compounds
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
US10941132B2 (en) 2016-01-05 2021-03-09 Hua Medicine (Shanghai) Ltd. Pyrazole derivatives
CN110312718B (zh) 2017-01-10 2023-02-28 拜耳公司 作为害虫防治剂的杂环烯衍生物
MX2019008229A (es) 2017-01-10 2019-10-24 Bayer Ag Derivados heterociclicos como agentes de control de plagas.
WO2021110574A1 (en) * 2019-12-02 2021-06-10 F. Hoffmann-La Roche Ag Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors
CN111416154B (zh) * 2020-05-22 2021-08-06 松山湖材料实验室 高电压锂离子电池电解液硅基吡啶添加剂、电解液及其电池
AU2022251771A1 (en) 2021-03-27 2023-09-21 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives
WO2023089049A2 (en) 2021-11-19 2023-05-25 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303199A (en) 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
US4711962A (en) 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
US4882343A (en) * 1987-08-28 1989-11-21 G. D. Searle & Co. Biarylalkylimidazole derivatives as anti-depressants
WO1991000277A1 (en) 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
DE69822638T2 (de) 1997-08-14 2005-02-24 F. Hoffmann-La Roche Ag Heterocyclische vinylether zur behandlung neurologischer krankheiten
AU780009B2 (en) 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
KR100515549B1 (ko) 2000-12-04 2005-09-20 에프. 호프만-라 로슈 아게 글루타메이트 수용체 길항제로서의 페닐에테닐 또는페닐에티닐 유도체
WO2003053922A2 (en) * 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5

Also Published As

Publication number Publication date
US7153874B2 (en) 2006-12-26
JP2006519802A (ja) 2006-08-31
AU2004220382A1 (en) 2004-09-23
TWI292318B (en) 2008-01-11
ZA200506834B (en) 2006-05-31
AU2004220382B2 (en) 2007-08-02
RU2005131165A (ru) 2007-04-20
CA2516682C (en) 2010-02-02
JP4404896B2 (ja) 2010-01-27
BRPI0408093A (pt) 2006-02-14
NO20054136L (no) 2005-09-26
PE20041061A1 (es) 2005-01-22
CA2516682A1 (en) 2004-09-23
RU2342383C2 (ru) 2008-12-27
SI1606277T1 (sl) 2008-08-31
PA8597301A1 (es) 2004-09-16
IL170129A (en) 2013-02-28
MXPA05009524A (es) 2005-10-18
HK1089443A1 (en) 2006-12-01
CN1759111A (zh) 2006-04-12
DK1606277T3 (da) 2008-08-18
PT1606277E (pt) 2008-07-08
AR043501A1 (es) 2005-08-03
ES2305739T3 (es) 2008-11-01
MY135491A (en) 2008-04-30
NO20054136D0 (no) 2005-09-06
CO5601027A2 (es) 2006-01-31
DE602004013746D1 (de) 2008-06-26
KR100742019B1 (ko) 2007-07-23
KR20050109074A (ko) 2005-11-17
CN100358889C (zh) 2008-01-02
PL1606277T3 (pl) 2008-10-31
EP1606277A1 (en) 2005-12-21
EP1606277B8 (en) 2008-10-15
WO2004080998A1 (en) 2004-09-23
ATE395345T1 (de) 2008-05-15
TW200423935A (en) 2004-11-16
US20040229917A1 (en) 2004-11-18
NZ541643A (en) 2008-03-28
CL2004000449A1 (es) 2005-01-07
EP1606277B1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
HRP20050774A2 (en) Imidazol-4-yl-ethylnyl-pyridine derivatives
UA74419C2 (uk) Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
WO2006107859A8 (en) Dihydropyridine compounds for neurodegenerative diseases and dementia
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
NO20025517D0 (no) Triazolderivater
WO2003076414A3 (en) Aryl substituted pyrimidines and the use thereof
TNSN05294A1 (en) Immunosuppressant compounds and compositions
MXPA05012461A (es) Compuestos y composiciones inmunosupresores.
EP1638551A4 (en) IMMUNOSUPPRESSIVE COMPOUNDS AND COMPOSITIONS
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2004071442A3 (en) Novel bicyclic compounds and compositions
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
ATE457985T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
RS20050892A (xx) Derivati imidazola kao antagonisti glutamatnih receptora
WO2007127393A3 (en) Treatment and screening methods for promoting neurogenesis
TW200801005A (en) Acetylenic piperazines as metabotropic glutamate receptor antagonists
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
ATE471322T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
WO2008061329A3 (en) PHα1B TOXIN, CDNA OF PHα1 B TOXIN GENE, PHARMACEUTICAL COMPOSITIONS CONTAINING PHα1B TOXIN, PROCESSES FOR THEIR OBTENTION AND PRODUCT
DOP2004000843A (es) Derivados de imidazol-4-il-etinil-piridina
WO2006135545A3 (en) A method for the prevention and/or treatment of neurodegenerative diseases characterized by administering an ep1 receptor antagonist
HRP20030956A2 (en) USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
HK1098668A1 (en) Use of 1,3-diaza-dibenzo Äe.hÜ azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
HK1098670A1 (en) Use of 3-aza-1-oxa-dibenzo Äe,hÜ azulenes for the manufacture of pharmaceutical formulations for thetreatment and prevention of central nervous syste m disease and disorders

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100226

Year of fee payment: 7

OBST Application withdrawn